Advancements in Lung Cancer Immunotherapy: Current Strategies and Future Directions
*Corresponding Author: Behzad Rahmat, Department of Respiratory Diseases, University of Bari, Italy, Email: behzadr273@gmail.comReceived Date: Oct 01, 2024 / Published Date: Oct 31, 2024
Citation: Behzad R (2024) Advancements in Lung Cancer Immunotherapy:Current Strategies and Future Directions. J Pulm Res Dis 8: 217.
Copyright: © 2024 Behzad R. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.
Abstract
Lung cancer remains one of the leading causes of cancer-related mortality worldwide. Recent advancements in immunotherapy have transformed the landscape of treatment for non-small cell lung cancer (NSCLC), the most common type of lung cancer. Immunotherapies, particularly immune checkpoint inhibitors, have demonstrated substantial improvements in survival rates and quality of life for patients. This article provides an overview of the current immunotherapeutic strategies in lung cancer treatment, including immune checkpoint inhibitors, cancer vaccines, adoptive T-cell therapies, and oncolytic virus therapies. Additionally, it explores the emerging approaches and challenges in the field, such as personalized immunotherapy, combination treatments, and the role of the tumor microenvironment. Lastly, the article discusses the future directions and the promise of innovative immunotherapeutic strategies in the fight against lung cancer.
